“…It has been used frequently in the functional assessment of pediatric pain, including both acute pain (Gidron et al, 1995;Barnum et al, 1998) and chronic pain such as headaches (e.g., Palermo and Kiska, 2005), fibromyalgia (e.g., Kashikar-Zuck et al, 2002), complex regional pain syndrome (e.g., Eccleston et al, 2004), juvenile rheumatoid arthritis (e.g., Reid et al, 2005), sickle cell disease (e.g., Peterson and Palermo, 2004), recurrent abdominal pain (e.g., Robins et al, 2002;Walker et al, 2005), irritable bowel syndrome (e.g., Claar et al, 1999), and inflammatory bowel disease (e.g., Tojek et al, 2002). The FDI also has served as an outcome measure in treatment intervention studies for pain patients, including a randomized clinical trial of behavioral treatment for abdominal pain (e.g., Robins et al, 2005), an evaluation of cognitive behavioral treatment for chronic pain , and an open-label trial of citalopram for treatment of recurrent abdominal pain (Campo et al, 2004).…”